The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Adjuvant chemotherapy for patients with rectal cancer
Vanessa Wookey, MD, Fox Chase Cancer Center, Philadelphia, PA, reflects upon the PROSPECT trial (NCT01515787) and the necessity of adjuvant chemotherapy in patients with node-negative low rectal cancer (RC). In the Phase II trial (NCT03548961) evaluating organ preservation in node-negative low RC, approximately a third of patients had achieved a complete response (CR), emphasizing patients who need chemotherapy post-surgery should be carefully selected in the clinic. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
